BXP Secures $1.2B Construction Loan for 343 Madison Avenue Office Tower – Commercial Observer

BXP announced it secured a $1.2B construction loan for its 930,000 sq ft, 46-story office tower at 343 Madison Ave in Midtown, with a four-year term plus a one-year extension option, from Wells Fargo, Bank of America Securities, BNY Mellon and J.P. Morgan. Completion is set for 2029; the project is 50% pre-leased. BXP reported Q2 2026 FFO of $283.4M ($1.78/share) and revenue of $895.7M.

Original reporting
Published Jul 29, 2026, 6:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 7:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BXP Secures $1.2B Construction Loan for 343 Madison Avenue Office Tower – Commercial Observer — source image
Decision brief

The 30-second read

$BXPBullishMed
01

Why it matters

The disclosed $1.2B construction loan and the project’s pre-leasing progress (50% now, targeting nearly 70% with additional tenants) are the key execution and demand signals for traders assessing BXP’s office development pipeline.

02

Market read

Traders can update BXP’s development risk and near-term capital-market narrative based on the new construction financing and disclosed leasing momentum.

03

What to watch

The article does not disclose the loan’s interest rate, covenants, or draw schedule, which can materially affect economics and downside risk.

Relevance 7/10Novelty 6/10Timing: today’s earnings call disclosure of the $1.2B construction loan and 343 Madison leasing status

Background

BXP is building a 930,000-square-foot, 46-story office tower at 343 Madison Avenue in Midtown, with financing arranged during its Q2 earnings call.

Company-level read

Ticker impact

$BXPBullishMedium confidence
Context

BXP announced a $1.2B construction loan for its 343 Madison Avenue tower, including a four-year term and a one-year extension option.

Expected impact

Moderately positive bias for BXP shares as the market weighs execution risk and leasing momentum.

Evidence & confidence

The article is a primary disclosure of project-level debt and provides concrete leasing milestones (50% pre-leased, anchor and expansion) plus stated FFO and revenue context from the same earnings call.

Market effects

Reinforces that large Class A office owners can still secure sizable construction debt, and that Manhattan leasing pricing power remains intact.

Highlights continued tight office supply and rent growth in Midtown near Grand Central, potentially supporting other NY landlord valuations.

Limited direct global spillover; primarily a US office REIT capital markets and leasing read-through.

Counterpoint

Pre-leasing strength may not fully offset office-cycle risk, and construction debt terms could still pressure returns if leasing or costs deteriorate before delivery.

Key entities

  • BXP

    REIT securing $1.2B construction loan for 343 Madison Avenue, with leasing and earnings-call updates.

  • Wells Fargo

    One of the financing sources for the $1.2B construction loan.

  • Bank of America Securities

    One of the financing sources for the $1.2B construction loan.

  • J.P. Morgan Chase

    One of the financing sources for the $1.2B construction loan.

  • C.V. Starr

    Signed a 275,000-square-foot anchor lease and expanded by two additional floors.

Related articles

$BXPMedAI 8/10

Did BXP’s (BXP) Upbeat Q2 Beat and Higher FFO Outlook Just Shift Its Investment Narrative?

BXP reported Q2 2026 earnings exceeding expectations and raised its full-year FFO outlook, citing improved business fundamentals. The company's investment narrative hinges on high-quality office and life science space in key markets, with risks tied to new developments and leasing. BXP's $1.2B construction loan for 343 Madison Avenue highlights both potential and risks. Analysts' earnings estimates for 2029 range from $290.1M to $343.6M, with revenue projections between $3.7B and $3.8B.

$BXPMedAI 8/10

BXP's $1.2 Billion 343 Madison Loan Advances a Major Growth Project

BXP closed a $1.2B loan for its $2B 343 Madison Ave project, reducing equity needs to $341M. The 4-year loan at Term SOFR + 2.50% (declining to +2.25% upon milestones) funds 60% of costs. BXP targets 7.5%-8% returns, pending leasing and construction progress. The project is 50% pre-leased, with delivery expected in late 2029.

$BXPMed

BXP, Inc. Q2 2026 Earnings Call Summary

Strategic Performance and Market Dynamics BXP delivered a strong second quarter, exceeding FFO guidance by $0.08 and raising the 2026 midpoint by $0.05, driven by faster-than-expected leasing and occupancy gains. Management attributes the leasing momentum to a 'very healthy environment' for premier workplaces, noting that AI is acting as a significant tailwind by driving space expansions and upgrades among tech and professional service firms.

$BXPMed

BXP Selling 7 Times Square Ground Lease

Boston Properties (BXP) is marketing the 7 Times Square ground lease via Eastdil Secured, hiring Will Silverman and Gary Phillips. BXP expects proceeds of $700 million to $750 million, with bids due soon. The 1.2M sq ft tower has a 99-year lease and is 91% occupied. The deal would test Times Square office demand.

$BXPMed

Q3 Financial Results 2025-26

Beximco Pharmaceuticals PLC (AIM: BXP) reported unaudited Q3 and nine-month results ended 31 March 2026. For nine months, net sales rose 13.1% to BDT 41,428.0m (£256.9m) and profit after tax increased 34.0% to BDT 7,048.6m (£43.7m). In Q3, net sales grew 8.1% to BDT 13,627.8m (£84.5m) and PAT rose 30.6% to BDT 2,254.4m (£14.0m).